Emerging Therapies Plaque Psoriasis

NPF Issues New Guidance Regarding COVID-19 Vaccines
January 22, 2021

New guidance statements related to COVID-19 vaccines and psoriatic disease patients have been published by the National Psoriasis Foundation (NPF) COVID-19 Task Force.

IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral Therapies
January 21, 2021

Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.

Ustekinumab associated with increased cardiovascular risk in some patients
December 22, 2020

A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.